



Press release

STADA expands its Consumer Healthcare portfolio for Pharmacies in Croatia

- STADA acquires Nemus Lex, a well-established Healthcare Company in the Vitamin Minerals supplement segment and integrates these brands into its Consumer Healthcare portfolio in Croatia
- The portfolio includes the well-known Pharmoval line with market-leading brand Imunosal, as well as another 5 brands counting total of 28 products, which puts STADA among the top ten in the Consumer Healthcare segment in Croatia
- STADA Croatia General Manager Karla Raffaelli: "Adding market-leading brands such as Pharmoval and Imunosal further strengthens STADA Croatia's position on the Croatian market."

Zagreb, Croatia. December 20th, 2022 – STADA Croatia has completed the acquisition of the local healthcare company Nemus Lex. The deal positions STADA Croatia among the top ten Consumer Healthcare companies in the Croatian market. Additionally, as the majority of the products are manufactured in Croatia, the local production is strengthened with potential for export to other markets. Structural integration will bring more operational flexibility that should significantly contribute to better presence and availability of top brands for pharmacies and end users.

The portfolio includes the well-known Pharmoval line with the market leading brand Imunosal, as well as another 5 brands counting total of 28 products within the Vitamin Mineral Supplement area.

Vorstand: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez
Aufsichtsratsvorsitzender: Dr. Günter von Au



The best known and strongest brand Imunosal is the leading line of immunity products in Croatian pharmacies, currently reaching approx. 20% of market share in the segment, offering eight different formulations suitable for children, adults and seniors.

The highlights in the acquired portfolio also include a wide range of products for most common health conditions such as Dibeticin (pre-diabetes), Brusnica Kompleks and D-Manoza Brusnica Kompleks (urinary health), Islandski Lisaj (cough), Lexoderm (chickenpox), Prunulac (constipation), Robi Comb and Liceguard (anti-lice), Silimarin 3-Aktiv (liver remedy), A-Petit (appetite booster), Forticor (cardiovascular health), Supravital (multi-vitamin), Zenosal Forte (sleeping aid) and Anorectal (anti-hemorrhoids).

“Adding market-leading brands such as Pharmoval and Imunosal further strengthens STADA Croatia’s position in the Croatian market. It is important to note that STADA Croatia will continue to support local production with potential for international expansion.” emphasizes Karla Raffaelli, STADA Croatia’s General Manager. “We look forward to further building Pharmoval and Imunosal brand awareness and bringing them even closer to community and online pharmacies as well as to the public.” Raffaelli continues.

Nothing changes for pharmacists and customers as a result of this acquisition. With STADA as a trusted partner, Croatian pharmacists can be sure they are offering their customers an appealing and comprehensive portfolio for a wide range of symptoms.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2021, STADA achieved group sales of EUR 3,249.5 million and reported earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 776.5 million. As of 31 December 2021, STADA employed 12,520 people worldwide.

Vorstand: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez
Aufsichtsratsvorsitzender: Dr. Günter von Au



Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

Vorstand: Peter Goldschmidt (CEO) / Simone Berger / Miguel Pagan Fernandez

Aufsichtsratsvorsitzender: Dr. Günter von Au